Advertisement
Advertisement
U.S. Markets open in 6 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.36-0.38 (-3.90%)
At close: 04:00PM EST
9.01 -0.35 (-3.74%)
Pre-Market: 08:49AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.74
Open9.68
Bid7.10 x 800
Ask9.73 x 900
Day's Range9.27 - 9.73
52 Week Range6.84 - 17.68
Volume519,701
Avg. Volume584,554
Market Cap774.086M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.67
  • Simply Wall St.

    We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector’s board of directors granted 8 (eight) new employees options to purchase an aggregate of 91,851 shares of the company’s common stock and restricted stock units (RSUs) for an aggregate of 40,961 shares of the company’s common stock.

  • GlobeNewswire

    Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

    AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in the brain SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, re

Advertisement
Advertisement